PM
PROF

Penbrook Management’s Profound Medical PROF Stock Holding History

Penbrook Management’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.3K Sell
12,075
-225
-2% -$1.51K 0.05% 101
2026
Q1 		$79.7K Buy
+12,300
New +$85K 0.06% 92

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.77B AUM 38.11% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Penbrook Management's PROF Position: Q2 2026 in Review

Penbrook Management reduced its Profound Medical (PROF) stake by 1.8% in Q2 2026, selling an estimated $1.51K and leaving 12,075 shares worth $80.3K. The position accounts for 0.05% of the portfolio, ranked #101.

Penbrook Management first reported a position in PROF in Q1 2026 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold PROF as of Q2 2026.

  • Penbrook Management held 12,075 shares of Profound Medical worth $80.3K as of Q2 2026.
  • Penbrook Management sold 225 Profound Medical shares in Q2 2026, an estimated $1.51K.
  • Profound Medical made up 0.05% of Penbrook Management's portfolio in Q2 2026, its #101 holding.
  • Penbrook Management first reported a position in Profound Medical in Q1 2026 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Profound Medical as of Q2 2026.

Based on Penbrook Management's 13F filing for Q2 2026, filed 23 Jul 2026.